Interleukin-17 promotes metastasis in an immunocompetent orthotopic mouse model of prostate cancer

American Journal of Clinical and Experimental Urology

Qiang Nie¹  Qiuyang Zhang²  David Cunningham³  Keshab R Parajuli⁴  Sen Liu⁵  Lin Ma⁶  Zhenbang Chen⁷  Allen Zhang⁸ 

[1] Department of Biochemistry and Cancer Biology, School of Medicine, Meharry Medical College, Nashville, Tennessee;Department of Orthopedic Surgery, Tulane University, New Orleans 70112, Louisiana;Department of Structural and Cellular Biology, Tulane University, New Orleans 70112, Louisiana;Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China;Lung Cancer Research Institute and Cancer Center, Guangdong General Hospital, Guangzhou, Guangdong Province, China;Tulane Cancer Center and Louisiana Cancer Research Consortium, New Orleans, Louisiana;Tulane Center for Aging, Tulane University, New Orleans, Louisiana;Tulane Center for Stem Cell Research and Regenerative Medicine, Tulane University, New Orleans, Louisiana

关键词: Prostate cancer;    metastasis;    interleukin-17;    orthotopic mouse model;    MPC3;   

DOI  :  

学科分类：医学（综合）

来源: e-Century Publishing Corporation

【 摘 要 】

Metastasis of prostate cancer causes substantial morbidity and mortality. The role of chronic inflammatory factors in promoting the development of prostate cancer metastasis remains unexamined due to a lack of immunocompetent animal models. Here we report an orthotopic mouse allograft model of prostate cancer that was used to assess interleukin-17’s role in prostate cancer metastasis. A luciferase gene was stably introduced into a mouse prostate cancer cell line MPC3, named as MPC3-luc. MPC3-luc cells were mixed with Matrigel™ and inoculated into C57BL/6 mouse prostates, with recombinant mouse interleukin-17 (IL-17) (treatment group) or without IL-17 (control group). Bioluminescent imaging was used to track the growth and metastasis of prostate cancer metastasis. Immunohistochemistry was performed to confirm metastasis. Mice in the IL-17 treatment group had significantly higher incidence of metastasis than mice in the control group. However, there was no detectable difference in primary prostate tumor growth. Metastases were confirmed as originating from prostate cancer through staining for luciferase protein expression. Our findings suggest that interleukin-17 promotes prostate cancer metastasis in an orthotopic mouse allograft model.

【 授权许可】

CC BY-NC